GEA 3162

GEA 3162 is an orally active compound that acts as a NO/ONOO⁻ donor. GEA 3162 significantly inhibits the activation of human polymorphonuclear leukocytes (PMNs) through the cGMP pathway, inhibits the release of inflammatory mediators, and exerts anti-inflammatory and protective effects. GEA 3162 induces apoptosis of neutrophils and bone marrow cells by activating caspase-2/3/8/9 through the ONOO⁻ pathway. GEA 3162 has a bidirectional effect in the rat gastric ulcer model: at low doses, it significantly reduces gastric mucosal damage, while at high doses, it aggravates the ulcer area. GEA 3162 can be used for research on inflammatory conditions such as gastric ulcers^[1].
In Vitro:GEA 3162 (1-100 μM) inhibits Ca ionophore A23187-induced LTB4 and beta-glucuronidase release, chemotactic peptide FMLP-induced chemotaxis and opsonized zymosan-triggered chemiluminescence dose-dependently in human PMNs^[1].
GEA 3162 (0-1 mM) inhibits LTB4 release from human PMNs dose-dependently^[1].
GEA 3162 (0-1 mM) suppresses β-glucuronidase release from A23187-activated PMNs dose-dependently^[1].
GEA 3162 (0-1 mM) is effective inhibitor of FMLP-induced chemotactic movement of human PMNs with IC₅₀ value of 6 μM^[1].
GEA 3162 increases the cyclic GMP levels more rapidly and at lower drug concentrations^[1].